

Evaluation Report for Category B, Subcategory 3.11 Application

Application Number:	2022-4585
Application:	New or Changes to the Product Label – New Pests
Product:	Authority Supreme Herbicide
Registration Number:	32562
Active ingredients (a.i.):	250 g/L Pyroxasulfone, 250 g/L Sulfentrazone
PMRA Document Number : 3437424	

Background

Authority Supreme Herbicide (Reg. No. 32562) is a suspension concentrate herbicide containing 250 g/L pyroxasulfone and 250 g/L sulfentrazone. It is registered for weed control/suppression in field pea, chickpeas, soybeans, sunflowers and field-grown conifers (including Christmas trees). Both sulfentrazone and pyroxasulfone provide extended, residual control of several susceptible weed species.

Purpose of Application

The purpose of the subject application is to amend the Authority Supreme Herbicide label to include Palmer amaranth as a weed controlled.

Chemistry, Health and Environmental Assessment

Chemistry, health, and environmental assessments were not required as there was no change to product chemistry, product formulation, or use pattern.

Value Assessment

The addition of Palmer amaranth to the Authority Supreme Herbicide label provides growers an alternative option to manage an aggressive, highly competitive weed species with a renowned reputation for developing resistance to herbicide groups, prior to crop planting or emergence.

The applicant submitted value information that included data from small plot field trials conducted between 2018 and 2020 throughout the United States of America. Results from the trials demonstrated that Authority Supreme Herbicide applied per label directions would result in acceptable control of Palmer amaranth.

Conclusion

The PMRA has completed an assessment of the subject application and has found the information sufficient to support the inclusion of Palmer amaranth as a weed controlled by Authority Supreme Herbicide.

References



3387934 2022, Authority Supreme Herbicide (PCP 32562) for control of Palmer amaranth, DACO: 10.1, 10.2.1, 10.2.2, 10.2.3.1, 10.2.3.3, 10.3.2, 10.3.3, 10.4, 10.5.1, 10.5.2, 10.5.3, 10.5.4, 10.5.5

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2022

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.